Item 8.01 Other Events.



On March 21, 2022, Travere Therapeutics, Inc. (the "Company") announced that it
has submitted a New Drug Application ("NDA") to the U.S. Food and Drug
Administration ("FDA") under Subpart H for accelerated approval of sparsentan
for the treatment of IgA nephropathy ("IgAN"). The Company expects to receive
notice regarding the acceptance of the NDA, as well as the timeline for NDA
review, from the FDA in May 2022.

Forward-Looking Statements



This Current Report on Form 8-K contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include references to the Company's current
expectations around the timeline for receiving notice regarding the acceptance
of the NDA and the timeline for NDA review. Such forward-looking statements are
based on current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and could
cause actual outcomes and results to differ materially from current
expectations. No forward-looking statement can be guaranteed. Among the factors
that could cause actual results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated with the
regulatory review and approval process, including the Subpart H accelerated
approval pathway. There is no guarantee that the FDA will accept for filing the
Company's NDA for sparsentan for IgAN under the Subpart H approval pathway, that
the FDA will grant accelerated approval of sparsentan for IgAN or that
sparsentan will be approved at all. In addition, such risks and uncertainties
may include those described in the Company's filings with the Securities and
Exchange Commission, including under the "Risk Factors" heading of the Company's
annual report on Form 10-K for the year ended December 31, 2021, as filed with
the SEC on February 24, 2022. You are cautioned not to place undue reliance on
any forward-looking statements as there are important factors that could cause
actual results to differ materially from those in any forward-looking
statements, many of which are beyond our control. Except to the extent required
by law, the Company undertakes no obligation to publicly update any
forward-looking statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description


      104              Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: March 21, 2022                                                  By:

/s/ Elizabeth E. Reed

Name: Elizabeth E. Reed

Senior Vice President, General

Title: Counsel and Secretary

© Edgar Online, source Glimpses